Effect of dapagliflozin on COVID-19 infection and risk of hospitalization.

Angel Salgado-BarreiraJose Seijas-AmigoMoises Rodriguez-MañeroMaría Piñeiro-LamasSonia EirasAlberto Cordero-FortJose Ramon Gonzalez-JuanateyAdolfo Figueiras

Published in: The Journal of antimicrobial chemotherapy (2023)

Use of dapagliflozin prior to SARS-CoV-2 infection was not associated with an increased risk of hospitalization, ICU admission, mortality or progression to severe COVID-19. However, it was associated with an increased risk of susceptibility to COVID-19 infection.

Keyphrases

coronavirus disease
sars cov
respiratory syndrome coronavirus
intensive care unit
emergency department
cardiovascular events
early onset
mechanical ventilation
risk factors
cardiovascular disease
drug induced